Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six months ended June 30, 2023.

Financial Results for the Six Months Ended June 30, 2023

Net Loss: The net loss attributable to common stockholders was $3.18 million, from operations, or a basic and diluted loss per share of $(0.13). For the same period in 2022, loss from operations was $2.45 million, or a basic and diluted loss per share attributable to common stockholders of ($0.35)

Cash Position: The Company had $40,458 in cash and cash equivalents as of June 30, 2023.

Financial Position: Total assets at June 30, 2023 was $1,025,236 which included $563,872 of current assets as compared to total assets at June 30, 2022 of $6,190,930 which included $4,323,632 of current assets. Total liabilities as at June 30, 2023 was $10,109,978 which included $4,940,473 of current liabilities compared to total liabilities at June 30, 2022 of $8,217,304 which included $3,420,295 of current liabilities.

Total Expenses: Total expenses for the six months ended June 30, 2023 was $2,650,920 compared to $3,143,805 for the six-month ended June 30, 2022.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION – UNAUDITED
(EXPRESS IN CANADIAN DOLLARS)
As at, Note June 30,
2023
$
December 31,
2022
$
Current assets
Cash 40,458 11,030
Other receivables 4 - 86,667
Sales tax receivable 122,645 276,135
Marketable securities 4 - 4,617,885
Prepaids and deposits 5 400,769 1,220,349
Total current assets 563,872 6,212,066
Non-current assets
Prepaids and deposits 5 460,167 678,916
Property and equipment 6 1,197 9,876
Total assets 1,025,236 6,900,858
Current liabilities
Accounts payable and accrued liabilities 14 4,855,211 5,371,916
Notes payable 8 85,262 85,204
Derivative liabilities 9 - 346,667
Total current liabilities 4,940,473 5,803,787
Non-current liabilities
Convertible debentures, net 7 5,169,505 4,696,974
Total liabilities 10,109,978 10,500,761
Shareholders' equity (deficiency)
Share capital 10 121,269,011 115,918,379
Contributed surplus 10 16,787,778 16,787,778
Equity portion of convertible debentures 7 175,756 175,756
Deficit (147,317,287 ) (136,481,816)
Total shareholders' equity (deficiency) (9,084,742 ) (3,599,903)
Total liabilities and shareholders' equity (deficiency) 1,025,236 6,900,858


CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS – UNAUDITED
(EXPRESS IN CANADIAN DOLLARS)
For the three-months ended, For the six-months ended,
Note June 30,
2023
$
June 30,
2022
$
June 30,
2023
$
June 30,
2022
$
Expenses
Finance cost 7 239,621 238,464 474,539 459,663
Corporate development 2,018 13,594 503,649 141,474
Depreciation 6 3,404 34,301 8,679 94,573
Consulting fees 1,523,776 703,895 3,456,714 2,127,768
Director and management fees 12 124,921 120,284 308,883 230,856
Foreign exchange loss (gain) (23,013 ) (53,964) (13,383 ) (25,776)
Insurance 20,445 289,529 49,169 548,874
Office and miscellaneous 96,484 22,541 235,150 240,523
Professional fees 136,849 385,479 462,470 992,633
Regulatory and filing fees 30,914 - 131,594 -
Research and development 101,750 652,486 245,084 1,702,011
Salaries 12 393,751 737,196 768,810 1,375,242
Total expenses 2,650,920 3,143,805 6,631,358 7,887,841
Other income (expenses)
Change in fair value of derivative liabilities 9 - 631,760 - (261,690)
Revaluation of marketable securities 4 (530,221 ) - (2,807,318 ) -
Other income - - 26,667 -
Other receivable provision 4 - - (1,285,365 ) -
Loss on s ettlement of debt 10 - - (5,425 ) -
Transaction costs - - (132,672 ) -
Total other income (expenses) (530,221 ) 631,760 (4,204,113 ) (261,690)
Loss for the period (3,181,141 ) (2,512,045) (10,835,471 ) (8,149,531)
Foreign currency translation adjustment - 61,561 - 61,561
Net loss and comprehensive loss for the period (3,181,141 ) (2,450,484) (10,835,471 ) (8,087,970)
Net loss per share – Basic and diluted from continuing operations (0.13 ) (0.35) (0.49 ) (1.31)
Weighted average number of shares outstanding – Basic and diluted 25,154,580 7,142,532 21,894,987 6,217,942

For more information, please review the Company's filed financial statements and management discussion on the SEDAR+ site.

About Mydecine Innovations Group

Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006—short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others.

Learn more at https://www.mydecine.com .

For more information, please contact:
Media Contact:
pr@mydecineinc.com

Investor Relations:
investorrelations@mydecineinc.com

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR+ at www.sedarplus.ca or the Company's website at www.mydecine.com.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved.

Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MYCO:CC
The Conversation (0)
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company's MYCO-005 and MYCO-006 families.

MYCO-005 Notice of Allowance: Aza-Substituted Psilocin Analogs and Methods of Synthesising the Same Unique Compound

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Innovations Group Announces Director Resignation

Mydecine Innovations Group Announces Director Resignation

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors.

The Company is in the process of identifying a qualified replacement director and will make any necessary announcements in due course.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, "Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same Unique Compound (US20230348380A1)".

This Composition of Matter patent underscores Mydecine's commitment to innovation in mental health therapeutics. MYCO-005, a novel compound, that mimics psilocin as an improved version engineered to act therapeutically similar to psilocin while dramatically reducing highly undesirable side effects from long-term sustained use of psilocybin and almost all-known classical serotonin agonists (LSD, DMT, etc.), specifically addressing valvular fibrosis concerns recognised by leading clinicians and FDA regulators. MYCO-005 is designed with selective binding to 5-HT2A receptors and does not bind to 5-HT2B receptors for both macro and microdosing.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Announces Update Regarding the Special Access Program

Mydecine Announces Update Regarding the Special Access Program

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company's news release of January 13, 2022 (the " Prior Release ") wherein the Company announced it would be launching the Special Access Support and Supply Program (" SASSP ") to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.

The Company would like to clarify that the access to Health Canada's Special Access Program (the " Program ") to assist potential patients with the use of Psilocybin and/or MDMA is exclusively through its partner, Applied Pharmaceutical Innovation (" API ") pursuant to the Health Canada license granted to Dr. Raimar Loebenberg (the " Partnership "). Pursuant to the Partnership, API may provide patients access to certain controlled substances, including Psilocybin and/or MDMA, however, Mydecine does not directly have the ability to grant patients access to controlled substances through the Program.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports October 2023 Performance Figures

Canadian Securities Exchange Reports October 2023 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2023.

October 2023 Operating Statistics

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—